Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN Stock

$920.69   -0.185388%
Add to favorites
Market Cap
$95.24B
LOW - HIGH [24H]
$916.66 - $948.42
VOLUME [24H]
$877.67K
P/E Ratio
20.35
Earnings per share
$45.24
ISIN
US75886F1075
Price   Prediction

Regeneron Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Regeneron Pharmaceuticals (REGN) stock price today is 920.69 USD on Tech Market Large (-0.19% on the day). Updated .

Regeneron Pharmaceuticals REGN Financial and Trading Overview

Regeneron Pharmaceuticals stock price 920.69 USD
Previous Close 922.4 USD
Open 936.37 USD
Bid 955.62 USD x 100
Ask 975 USD x 2500
Day's Range 916.66 - 948.42 USD
52 Week Range 591.52 - 991.73 USD
Volume 856.78K USD
Avg. Volume 804.03K USD
Market Cap 95.24B USD
Beta (5Y Monthly) 0.095
PE Ratio (TTM) 20.351236
EPS (TTM) 45.24 USD
Forward Dividend & Yield 3.76 (0.41%)
Ex-Dividend Date November 20, 2026
1y Target Est 991 USD

REGN Valuation Measures

Enterprise Value 86.06B USD
Trailing P/E 20.351236
Forward P/E 12.84823
PEG Ratio (5 yr expected) 1.15
Price/Sales (ttm) 5.636972
Price/Book (mrq) 2.7571678
Enterprise Value/Revenue 5.094
Enterprise Value/EBITDA 15.241

Trading Information

Regeneron Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.095
52-Week Change 22.15%
S&P500 52-Week Change 8.67%
52 Week High 991.73 USD
52 Week Low 591.52 USD
50-Day Moving Average 826.97 USD
200-Day Moving Average 750.64 USD

REGN Share Statistics

Avg. Volume (3 month) 804.03K USD
Avg. Daily Volume (10-Days) 916.83K USD
Shares Outstanding 101.63M
Float 96.36M
Short Ratio 2.93
% Held by Insiders 2.14%
% Held by Institutions 92.34%
Shares Short 2.22M
Short % of Float 2.27%
Short % of Shares Outstanding 2.13%

Dividends & Splits

Trailing Annual Dividend Rate 3.7
Trailing Annual Dividend Yield 0.40%
5 Year Average Dividend Yield N/A
Payout Ratio 0.08180001
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 28.51%
Operating Margin (ttm) 30.38%
Gross Margin 46.73%
EBITDA Margin 33.41%

Management Effectiveness

Return on Assets (ttm) 7.58%
Return on Equity (ttm) 14.94%

Income Statement

Revenue (ttm) 16.9B USD
Revenue Per Share (ttm) 164.24 USD
Quarterly Revenue Growth (yoy) 36.29%
Gross Profit (ttm) 7.9B USD
EBITDA 5.65B USD
Net Income Avi to Common (ttm) 4.82B USD
Diluted EPS (ttm) 45.24
Quarterly Earnings Growth (yoy) 33.50%

Balance Sheet

Total Cash (mrq) 9.3B USD
Total Cash Per Share (mrq) 92.69 USD
Total Debt (mrq) 2.71B USD
Total Debt/Equity (mrq) 8.08 USD
Current Ratio (mrq) 3.353
Book Value Per Share (mrq) 333.926

Cash Flow Statement

Operating Cash Flow (ttm) 4.85B USD
Levered Free Cash Flow (ttm) 2.58B USD

Profile of Regeneron Pharmaceuticals

Country United States
State NY
City Tarrytown
Address 777 Old Saw Mill River Road
ZIP 10591-6707
Phone 914 847 7000
Website https://www.regeneron.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 15410

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Q&A For Regeneron Pharmaceuticals Stock

What is a current REGN stock price?

Regeneron Pharmaceuticals REGN stock price today per share is 920.69 USD.

How to purchase Regeneron Pharmaceuticals stock?

You can buy REGN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Regeneron Pharmaceuticals?

The stock symbol or ticker of Regeneron Pharmaceuticals is REGN.

Which industry does the Regeneron Pharmaceuticals company belong to?

The Regeneron Pharmaceuticals industry is Biotechnology.

How many shares does Regeneron Pharmaceuticals have in circulation?

The max supply of Regeneron Pharmaceuticals shares is 103.45M.

What is Regeneron Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Regeneron Pharmaceuticals PE Ratio is 20.35123600 now.

What was Regeneron Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Regeneron Pharmaceuticals EPS is 45.24 USD over the trailing 12 months.

Which sector does the Regeneron Pharmaceuticals company belong to?

The Regeneron Pharmaceuticals sector is Healthcare.

Regeneron Pharmaceuticals REGN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us S&P 500 (Yahoo.com) GSPC US 6910.39 USD —
-3.7
4.73B USD — 6882.66 USD — 7198.67 USD — — 4.73B USD —
us US100 NDX US 25028.98 USD —
-5.61
2.69B USD — 24910.48 USD — 26429.09 USD — — 2.69B USD —
us S&P 500 INDEX SPX US 6910.39 USD —
-3.7
505.58M USD — 6882.66 USD — 7198.67 USD — — 505.58M USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3815.19 USD —
-1.22
121.01M USD — 3805.63 USD — 3911.38 USD — — 121.01M USD —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2214.31 USD —
-0.8
— — 2209.33 USD — 2262.42 USD — — — —
us US Tech Global Select Market Com NQGS US 11139.01 USD —
-5.31
— — 11086.73 USD — 11742.47 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us US Tech-100 PM Settlement Value XQC US 16331.98 USD —
+1.13
— — 16331.98 USD — 16331.98 USD — — — —
us The Capital Strength Index NQCAPST US 3680.28 USD —
-0.78
— — 3672.87 USD — 3759.02 USD — — — —
us US Tech-100 Notional Net Total R XNDXNNR US 29196.94 USD —
-5.6
— — 29058.69 USD — 30830.08 USD — — — —
us US Tech-100 ESG Net Notional Tot NDXESG24 US 2058.89 EUR 2259.54 USD
-5.84
— — 2051.84 EUR 2251.8 USD 2178.71 EUR 2391.04 USD — — —
us US Tech-100 Micro Index XND US 250.29 USD —
-5.61
— — 249.11 USD — 264.29 USD — — — —
us US Tech-100 Equal Weighted NDXE US 8899.48 USD —
-4.18
— — 8869.11 USD — 9299.32 USD — — — —
us US Tech Composite Total Return XCMP US 27958.09 USD —
-5.28
— — 27828.65 USD — 29466.09 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech-100 Pre Market Indicator QMI US 26284.09 USD —
-0.88
— — 25923.02 USD — 26284.09 USD — — — —
us US Tech-100 Reduced Value Index NQX US 5005.8 USD —
-5.61
— — 4982.1 USD — 5285.86 USD — — — —
us US Tech US Price Setters Index NQPRCE US 3057.59 USD —
-1.54
— — 3050.97 USD — 3134.72 USD — — — —
$2.09T
Total marketcap
$119.93B
Total volume
BTC 57.99%   •   ETH 9.83%
Dominance
Select currency